Floatz logo

ima950

Glioblastoma, Adult

University Hospital, GenevavaccinePhase 1/2Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
31/ 100
Competitive Position
95/ 100

Competitive context

23 Active assets in the Glioblastoma, Adult cohort.

Asset / SponsorPhaseRating
Temsirolimus
University Hospital Heidelberg
Phase 2BBB
Cediranib
Lawrence Recht
Phase 2BBB
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
National Cancer Institute (NCI)
Phase 2BB
Irinotecan
NaviFUS Corporation
Phase 3BB
Sorafenib
National Cancer Institute (NCI)
Phase 2BB

View all 50 →

Same molecule, other indications

ima950 is also rated in:

central nervous system neoplasmDormant
CCC
Indicative ·
52 / 100
View asset →
central nervous system neoplasmDormant
CC
Indicative ·
46 / 100
View asset →
brain gliomaDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →